# Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China

> **NCT02040246** · PHASE4 · COMPLETED · sponsor: **RenJi Hospital** · enrollment: 107 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Repaglinide
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02040246
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2013-12
- **Final completion:** 2014-01
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2014-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02040246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02040246, "Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02040246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*